Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
downgraded at Goldman to Neutral. Rate negotiations will likely be pushed out. $37 price target.
upgraded at Keybanc from Hold to Buy. $20 price target. Industry has passed an important inflection point.
upgraded at Needham from Hold to Buy, Needham & Company said. Company has several potential near-term catalysts in its pipeline.
upgraded at Piper from Neutral to Overweight, Piper Jaffray said. $22 price target. Consensus earnings estimates remain too low.
downgraded at Soleil to Hold, Soleil Securities said. Valuation call, as the stock has outperformed the broader market by 55% since last April. $35 price target.
upgraded at Citigroup from Hold to Buy, Citigroup said. $107 price target. Company can deliver core growth, despite the recent distraction from the ARG bid.
rated new Buy at Jefferies. $46 price target. Company has emerging markets exposure and generates solid free cash flow.
downgraded at Credit Suisse to Underperform from Neutral on limited growth in pipeline, Credit Suisse said. Price target lowered to $35 from $38.
rated new Buy at Goldman Sachs. New products should drive earnings growth. $30 price target.
Expeditors International of Washington
downgraded at Credit Suisse to Neutral from Outperform as it is no longer a compelling opportunity, Credit Suisse said. Price target cut to $57 from $61.
downgraded at Citigroup from Buy to Hold, Citigroup said. $35 price target. CLDA deal will dilute near-term earnings.
( HOC) upgraded at RBC from Sector Perform to Outperform, RBC Capital said. $66 price target. FTO merger makes strategic sense.
upgraded at Argus from Hold to Buy, Argus Research said. Valuation call, based on a $66 price target.
rated new Buy at Janney Montgomery. $75 price target. Company is leveraged to increased spending by utilities.
upgraded at Argus from Sell to Hold. Valuation call.
rated new Sell at Goldman Sachs. Company is facing decelerating growth. $17 price target.
downgraded at Needham from Hold to Underperform, Needham & Company said. AMZN strategy will add increased competition.
upgraded at Goldman from Neutral to Buy, Goldman Sachs said. $45 price target. Estimates also boosted, as the company is seeing higher solar and renewables demand.
( PRX) initiated at Barclays with an Overweight rating. Zymafos in stage III is attractive , Barclays said. 2010 and 2011 EPS estimates set at $0.73 and $0.67, respectively.
downgraded at Credit Suisse to Neutral from Outperform on unpredictable revenue, and high expectations, Credit Suisse said. Price target slashed to $9 from $13.50.
upgraded at Goldman from Neutral to Buy, Goldman Sachs said. Rapid growth in viewing TV and movies online will boost sales and margins. $40 price target.
This article was written by a staff member of TheStreet.